Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Liposomal Doxorubicin

Liposomal Doxorubicin anthracycline doxorubicin by reducing the drug’s cardiotoxicity, but maintaining its antitumor efficacy. Liposomal doxorubicin plus cyclophosphamide is no less effective than conventional doxorubicin or epirubicin plus cyclophosphamide in the first-line treatment of women with metastatic breast cancer. In addition, the drug is significantly less cardiotoxic than conventional doxorubicin. The median cumulative dose to the first cardiac event for liposomal doxorubicin is higher than that for conventional doxorubicin; the potential to use dox- orubicin for a longer period of time may benefit a number of patients. Liposomal doxorubicin has also shown potential as part of a chemotherapy regimen in patients with non-Hodgkin lymphoma (NHL). Thus, liposomal doxorubicin represents an important advance in terms of offering reduced cardiotoxicity compared with conventional doxorubicin, and can be used in preference to conventional doxorubicin in a combination regimen with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. The rationale used as the basis for the design of intravenous liposomal doxorubicin is that the liposomes cannot Pharmacologic exit the circulation in healthy tissues, but can exit through leaky tumor-associated vessels. In animal models, Properties liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, and reduces mammary tumor growth to a significantly greater extent http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Liposomal Doxorubicin

Dando, Toni; Keating, Gillian
American Journal of Cancer , Volume 4 (3) – Aug 10, 2012
Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/liposomal-doxorubicin-g7x5i2624T
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504030-00006
Publisher site
See Article on Publisher Site

Abstract

anthracycline doxorubicin by reducing the drug’s cardiotoxicity, but maintaining its antitumor efficacy. Liposomal doxorubicin plus cyclophosphamide is no less effective than conventional doxorubicin or epirubicin plus cyclophosphamide in the first-line treatment of women with metastatic breast cancer. In addition, the drug is significantly less cardiotoxic than conventional doxorubicin. The median cumulative dose to the first cardiac event for liposomal doxorubicin is higher than that for conventional doxorubicin; the potential to use dox- orubicin for a longer period of time may benefit a number of patients. Liposomal doxorubicin has also shown potential as part of a chemotherapy regimen in patients with non-Hodgkin lymphoma (NHL). Thus, liposomal doxorubicin represents an important advance in terms of offering reduced cardiotoxicity compared with conventional doxorubicin, and can be used in preference to conventional doxorubicin in a combination regimen with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. The rationale used as the basis for the design of intravenous liposomal doxorubicin is that the liposomes cannot Pharmacologic exit the circulation in healthy tissues, but can exit through leaky tumor-associated vessels. In animal models, Properties liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, and reduces mammary tumor growth to a significantly greater extent

Journal

American Journal of Cancer – Springer Journals

Published: Aug 10, 2012

References

  • Postmenopausal metastatic breast cancer: a review of first-line treatment options
    Assersohn, L.; Johnston, S.R.D.
  • Liposomal doxorubicin (Myocet) and conventional anthracyclines: a comparison
    Marty, M.
  • Cardiac safety of liposomal anthracyclines
    Safra, T.
  • Congestive heart failure in patients treated with doxorubicin
    Swain, S.M.; Whaley, F.S.; Ewer, M.S.
  • Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
    Batist, G.; Barton, J.; Chaikin, P.
  • Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention
    Pai, V.B.; Nahata, M.C.
  • Improving the therapeutic index when using Myocet in the treatment of metastatic breast cancer
    Batist, G.
  • Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate)
    Swenson, C.E.; Perkins, W.R.; Roberts, P.
  • Comparison of free and liposome encapsulated doxorubicin tumor drug uptake antitumor efficacy in the SC115 murine mammary tumor
    Mayer, L.D.; Bally, M.B.; Cullis, P.R.
  • Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
    Swenson, C.E.; Bolcsak, L.E.; Batist, G.
  • Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
    Mross, K.; Niemann, B.; Massing, U.
  • Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
    Batist, G.; Ramakrishnan, G.; Rao, C.S.
  • Doxorubicin fluorescence in a human breast carcinoma (MX-1), after treatment with liposome-associated or free doxorubicin [abstract no. 3327]
    Roberts, P.; Janoff, A.S.; Mayhew, E.
  • EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer
    Hamilton, A.; Biganzoli, L.; Coleman, R.
  • TLC D-99 can be safely administered to patients with advanced hepatobiliary carcinomas and severe hepatobiliary dysfunction [abstract no. 1214]
    Iannitti, D.; Rathore, R.; Safran, H.
  • Liposome-encapsulated doxorubicin compared with conventional doxorubicin a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
    Harris, L.; Batist, G.; Belt, R.
  • Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer
    Chan, S.; Davidson, N.; Juozaityte, E.
  • Improved therapeutic index of TLC D-99 (liposome-encapsulated doxorubicin) compared to free doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin [abstract no. 405]
    Batist, G.; Harris, L.; Azarnia, N.
  • TLC D99 (D, Myocet) and herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis [abstract no. 216]
    Theodoulou, M.; Campos, S.M.; Batist, G.
  • Updated results of a phase II study (M77035) of Myocet® combined with weekly Herceptin ®and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC) [abstract no. 3041]
    Cortes, J.; Climent, M.; Lluch, A.
  • Gemcitabine, myocet and docetaxel for primary treatment of breast cancer [abstract no. v269]
    Schmid, P.; Krocker, J.; Dieing, A.
  • Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
    Valero, V.; Buzdar, A.U.; Theriault, R.L.
  • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma
    Coiffier, B.; Lepage, E.; Briere, J.
  • Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin’s lymphoma: results of therapy and correlates of response
    Levine, A.M.; Tulpule, A.; Espina, B.
  • A phase I/II trial of liposomal doxorubicin (TLC-D99, myocet) in combination with cyclophosphamide, vincristine, and prednisone (COMP) for newly diagnosed intermediate and high grade non-Hodgkin’s lymphoma (NHL) [abstract no. 329]
    Tulpule, A.; Espina, B.M.; Berman, N.
  • The MYOCAN study: a phase II study of cyclophosphamide, oncovin, Myocet™, and prednisone plus rituximab (R-COMP) in the treatment of elderly patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) [abstractno. 4586]
    Federico, M.; Dyer, M.J.S.; Caballero, M.D.
  • Goals and objectives in the management of metastatic breast cancer
    Chung, C.T.; Carlson, R.W.
  • Chemotherapy for metastatic breast cancer: report of a European expert panel
    Crown, J.; Dieras, V.; Kaufmann, M.
  • Liposomal anthracyclines in metastatic breast cancer: clinical update
    Rivera, E.
  • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HC1 (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    O’Brien, M.E.R.; Wigler, N.; Inbar, M.
  • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    Slamon, D.J.; Leyland-Jones, B.; Shak, S.
  • Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
    Shapiro, C.L.; Ervin, T.; Welles, L.